Search the Epitope Variant and Escape Mutation Database

Help

Found 1 matching record:

Displaying record number 54498

HXB2 Location Gag(77-85) Gag Epitope Map
View variants at this location

SLYNTVATL

`SLYNTiATL`		non-susceptible form; susceptible form
`SLYNTVAvL`		observed variant
`SLfNTVAvL`		escape documented in this paper
`SLfNTVATL`		diminished HLA binding or increased off-rate; susceptible form
`SLfNTiATL`		diminished response
`SLfNTiAvL`		escape documented in this paper; TCR related mutation
`SLhNaVAvL`		susceptible form
`SLYNTiAvL`		diminished response
`SLYNTiAiL`		observed variant
`SLfNTVATv`		susceptible form
`SLYNaVATL`		susceptible form
`SLYNlVAvL`		diminished HLA binding or increased off-rate
`SLYNTVAif`		diminished HLA binding or increased off-rate
`SLfNaVATL`		reversion; susceptible form
`SLfNaVAvL`		susceptible form
`SLfNmVATL`		susceptible form
`SLYNTVsTL`		susceptible form
`SLYNTitvL`		susceptible form
`SLYNTisvL`		susceptible form

Epitope Name SL9

Species (MHC/HLA) human(A2)

Variant Details

Showing all: 19 variant(s).

Variant ID.	`467`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTiATL`
Mutations	V/I
Epitope Location	V6I
HXB2 Location	V82I
Mutation Type	NSF: non-susceptible form SF: susceptible form
Note	Variant present in 8% of 76 A2+ patients. Bound strongly to HLA-A2 (binding affinity was 94 nM). Was recognized by some A2+ patient's PBMCs and not recognized by others.

Variant ID.	`468`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTVAvL`
Mutations	T/V
Epitope Location	T8V
HXB2 Location	T84V
Mutation Type	OV: observed variant
Note	Variant present in 4% of A2+ patients. Bound strongly to HLA-A2 (binding affinity was 20 nM). Was not present in the patients tested for EliSpot responses.

Variant ID.	`469`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTVAvL`
Mutations	Y/F T/V
Epitope Location	Y3F T8V
HXB2 Location	Y79F T84V
Mutation Type	E: escape documented in this paper
Note	Positively selected transition variant present in 5% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses. Not well recognized by patient PBMCs.

Variant ID.	`470`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTVATL`
Mutations	Y/F
Epitope Location	Y3F
HXB2 Location	Y79F
Mutation Type	DHB: diminished HLA binding or increased off-rate SF: susceptible form
Note	Positively selected transition variant present in 16% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses but was somewhat weaker compared to other variants. Recognized by patient PBMCs.

Variant ID.	`471`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTiATL`
Mutations	Y/F V/I
Epitope Location	Y3F V6I
HXB2 Location	Y79F V82I
Mutation Type	DR: diminished response
Note	Transition variant present in 7% of A2+ patients. Intermediate recognition by patient PBMCs.

Variant ID.	`472`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTiAvL`
Mutations	Y/F V/I T/V
Epitope Location	Y3F V6I T8V
HXB2 Location	Y79F V82I T84V
Mutation Type	E: escape documented in this paper TCR: TCR related mutation
Note	Positively selected escape variant present in 7% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses but the responses were usually weaker than to other variants. Assumed to impair TCR binding.

Variant ID.	`473`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLhNaVAvL`
Mutations	Y/H T/A T/V
Epitope Location	Y3H T5A T8V
HXB2 Location	Y79H T81A T84V
Mutation Type	SF: susceptible form
Note	A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.

Variant ID.	`474`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTiAvL`
Mutations	V/I T/V
Epitope Location	V6I T8V
HXB2 Location	V82I T84V
Mutation Type	DR: diminished response
Note	Positively selected transition variant present in 11% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses. Not well recognized by patient PBMCs.

Variant ID.	`475`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTiAiL`
Mutations	V/I T/I
Epitope Location	V6I T8I
HXB2 Location	V82I T84I
Mutation Type	OV: observed variant
Note	A minor variant found in one patient.

Variant ID.	`476`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNTVATv`
Mutations	Y/F L/V
Epitope Location	Y3F L9V
HXB2 Location	Y79F L85V
Mutation Type	SF: susceptible form
Note	A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.

Variant ID.	`477`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNaVATL`
Mutations	T/A
Epitope Location	T5A
HXB2 Location	T81A
Mutation Type	SF: susceptible form
Note	A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.

Variant ID.	`478`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNlVAvL`
Mutations	T/L T/V
Epitope Location	T5L T8V
HXB2 Location	T81L T84V
Mutation Type	DHB: diminished HLA binding or increased off-rate
Note	A minor variant found in one patient. HLA-binding affinity was not sufficient to elicit CTL responses.

Variant ID.	`479`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTVAif`
Mutations	T/I L/F
Epitope Location	T8I L9F
HXB2 Location	T84I L85F
Mutation Type	DHB: diminished HLA binding or increased off-rate
Note	A minor variant found in one patient. HLA-binding affinity was not sufficient to elicit CTL responses.

Variant ID.	`480`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNaVATL`
Mutations	Y/F T/A
Epitope Location	Y3F T5A
HXB2 Location	Y79F T81A
Mutation Type	R: reversion SF: susceptible form
Note	An unusual variant resulting in strong response. This is suggested to be a transient reversion variant. HLA-binding affinity was sufficient to elicit CTL responses.

Variant ID.	`481`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNaVAvL`
Mutations	Y/F T/A T/V
Epitope Location	Y3F T5A T8V
HXB2 Location	Y79F T81A T84V
Mutation Type	SF: susceptible form
Note	A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.

Variant ID.	`482`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLfNmVATL`
Mutations	Y/F T/M
Epitope Location	Y3F T5M
HXB2 Location	Y79F T81M
Mutation Type	SF: susceptible form
Note	A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.

Variant ID.	`483`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTVsTL`
Mutations	A/S
Epitope Location	A7S
HXB2 Location	A83S
Mutation Type	SF: susceptible form
Note	Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.

Variant ID.	`484`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTitvL`
Mutations	V/I A/T T/V
Epitope Location	V6I A7T T8V
HXB2 Location	V82I A83T T84V
Mutation Type	SF: susceptible form
Note	Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.

Variant ID.	`485`
Epitope Seq.	`SLYNTVATL`
Variant Seq.	`SLYNTisvL`
Mutations	V/I A/S T/V
Epitope Location	V6I A7S T8V
HXB2 Location	V82I A83S T84V
Mutation Type	SF: susceptible form
Note	Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.

References

Iversen2006 Astrid K. N. Iversen, Guillaume Stewart-Jones, Gerald H. Learn, Natasha Christie, Christina Sylvester-Hviid, Andrew E. Armitage, Rupert Kaul, Tara Beattie, Jean K. Lee, Yanping Li, Pojchong Chotiyarnwong, Tao Dong, Xiaoning Xu, Mark A. Luscher, Kelly MacDonald, Henrik Ullum, Bente Klarlund-Pedersen, Peter Skinhøj, Lars Fugger, Søren Buus, James I. Mullins, E. Yvonne Jones, P. Anton van der Merwe, and Andrew J. McMichael. Conflicting Selective Forces Affect T Cell Receptor Contacts in an Immunodominant Human Immunodeficiency Virus Epitope. Nat. Immunol., 7(2):179-189, Feb 2006. PubMed ID: 16388312. Show all entries for this paper.